Why a Coronavirus Vaccine Won't Hurt Netflix
There is little doubt that Netflix (NASDAQ: NFLX) has benefited from the pandemic. Worldwide orders to stay home caused massive demand for binge-worthy shows. With news that a jointly developed COVID-19 vaccine from Pfizer and BioNTech appeared to be more than 90% effective in a Phase 3 study, shares of so-called stay-at-home stocks have fallen. Fortunately, this short-term thinking presents potential Netflix investors an opportunity. The streaming giant was a solid growth story before COVID-19, and nothing has changed.
When Netflix reported its most recent earnings, investors seemed disappointed because the company only added 2.2 million subscribers, compared to expectations for 2.5 million. However, Netflix's 2020 overall subscriber numbers reveal the streaming giant is still playing with a massive lead.
Quarterly global subscriber gains
Source Fool.com
